Skip to search formSkip to main contentSkip to account menu

remogliflozin etabonate

An orally available prodrug of remogliflozin, a benzylpyrazole glucoside-based inhibitor of renal sodium-glucose co-transporter subtype 2 (SGLT2… 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

GlucosidesPyrazoles

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
An Open-Label, Single-Period, Two-Stage, Single Oral Dose Pharmacokinetic Study of Remogliflozin Etabonate Tablet 100 and 250 mg in Healthy Asian Indian Male Subjects Under Fasting and Fed Conditions
Background and objective Remogliflozin etabonate is an orally available prodrug of remogliflozin, an inhibitor of renal sodium… 
2019
2019
A case series of five hypertensive type 2 diabetes patients showing reduction in blood pressure and mean arterial pressure reduction in ambulatory blood pressure monitoring with remogliflozin…
Introduction. Hypertension is commonly occurring in type 2 diabetes and metabolic syndrome and inflammation are a well-known part… 
2015
2015
Pharmacokinetics and Pharmacodynamics of the SGLT2 Inhibitor Remogliflozin Etabonate in Subjects with Mild and Moderate Renal Impairment
Remogliflozin etabonate (RE), the prodrug of remogliflozin, is an inhibitor of the sodium glucose–dependent renal transporter 2… 
Review
2015
Review
2015
Remogliflozin etabonate : a novel SGLT2 inhibitor for treatment of diabetes mellitus.
INTRODUCTION Inhibitors of sodium-glucose co-transporter type 2 (SGLT2) represent a new class of anti-hyperglycemic agents with a… 
2013
2013
Regional gastrointestinal delivery of remogliflozin etabonate in humans
Remogliflozin etabonate (RE) is the prodrug of remogliflozin (R), an inhibitor of renal glucose transport designed to reduce… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)